Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Neoplasms 6Multiple Myeloma 4Fractures, Bone 4Osteoporosis 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Giant Cell Tumor of Bone 2Bone Metastases 2Bone Diseases 2Parathyroid Neoplasms 1Paraproteinemias 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Mastocytosis, Systemic 1Lymphoma 1Hyperparathyroidism, Primary 1Hormone Refractory Prostate Cancer 1Hematologic Neoplasms 1Hematologic Diseases 1Cataract 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Diseases 1Bone Neoplasms 1

Interventions

Zoledronic Acid 3Denosumab 3Vitamin D 2Risedronic Acid 2Letrozole 2Toremifene 1Ibandronic Acid 1Geritol 1Calcium Carbonate 1Calcium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Bone Diseases, Metabolic × Denosumab × Clear all
NCT00089661 2018-10-17

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Amgen

Phase 3 Completed
252 enrolled 13 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms

NCT00980174 2018-10-17

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Amgen

Phase 3 Completed
242 enrolled 19 charts
Endocrine

Bone Diseases, Metabolic, Osteoporosis, Multiple Endocrine Neoplasia Type 1

NCT00925600 2017-05-30

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Amgen

Phase 3 Completed
769 enrolled 21 charts
Genitourinary

Bone Diseases, Metabolic, Cataract, Neoplasms, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡